High-throughput Genotyping

NGS-based target enrichment methods for higher genotyping efficiency in plant and animal research

Overview

For Molecular Breeding, the Availability and Easy Accessibility of Genomic Resources is a Prerequisite

Although technological advances have provided a range of resources like molecular markers, genetic linkage maps, whole genome sequences, and transcriptomes, agricultural genomics has been facing many challenges.


Celemics provides the solution with our high-throughput genotyping panel.


We have utilized NGS and hybridization-based capture technology, whereby a high number of regions of interest are simultaneously enriched using specifically designed probe, to provide new insights into different agricultural genomics research.

High-Throughput Genotyping Panel
Features & Benefits

NGS-based Target Enrichment
Sequencing Assay

Utilizing NGS-based target enrichment method for higher accuracy and cost-effective experiment compared to conventional methods such as conventional GBS, PCR, and microarray

Comprehensive Analysis with High Accuracy

Perform comprehensive assay of 100 to 10,000 markers with minimized false-negative and false-positives as well as for discovering novel SNPs

Outstanding Performance Regardless of Various Origins

Receive high-quality results enabled by species-specifically designed blocking oligos across all types of origins

Maximized Analytic Efficiency

Benefit from Celemics’ library preparation kits, target capture technology, and multiplexing indices specifically designed for high-throughput genotyping

Comparison with Conventional Technologies

Advantages Disadvantage
Conventional GBS 1. Sequencing of multiple samples due to lower amount of data required compared to WGS 1. Limited biomarkers available due to limited conserved regions, reducing overall resolution
2. Unable to detect SNPs in the restriction sites
Microarray
1. Higher reproducibility than conventional
GBS
1. Hard to customize new targets (novel biomarkers)
2. Low flexibility to meet various kinds of genotyping
PCR 1. Cost-effective for low number of samples 2. Easy and fast analysis 1. Limited number of biomarkers to analyze at once
2. Inappropriate for mass-analysis of biomarkers
Celemics Target Enrichment 1. Cost saving : Highly cost-effective when assessing multiple samples
2. Flexible customization : Novel biomarkers can be added or removed
3. Comprehensive analysis : Including novel SNP discovery
4. Exceptional performance : Celemics proprietary blocking oligo design technology
5. Wide compatibility : Compatible with a wide range of sample types

Related Products

Customized NGS Panel

Customization to Next Level; tailored NGS panel customization and assay optimization

related-product

Highly optimized, user- convenient NGS library preparation kit for all Celemics panels

Celemics Analysis Service

End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis

Streptavidin Bead

Incomparable quality magnetic bead for simple, flexible, and reproducible purification

References

Exp Cell Res

The combination of osimertinib with Raf inhibitor overcomes osimertinib resistance induced by KRAS amplification in EGFR-mutated lung cancer cells

Lee T-G, Kang H-M, Kim SY, Kim H-R, Kim CH. The combination of osimertinib with Raf inhibitor overcomes osimertinib resistance induced by KRAS amplification in EGFR-mutated lung cancer cells. Exp Cell Res. 2023;430(1):113722.

 

10.1016/j.yexcr.2023.113722


View Detail >

Eskisehir Med J

SPECTRUM OF GERMLINE CANCER SUSCEPTIBILITY GENE MUTATIONS IN BREAST AND OVARIAN CANCER PATIENTS IN THE BLACK SEA REGION OF TURKEY: SINGLE CENTER EXPERIENCE

Çitli Ş, Dağcıoğlu Y, Aydın E, Kurtçu K. Spectrum of germline cancer susceptibility gene mutations in breast and ovarian cancer patients in the Black Sea region of turkey: Single center experience. esmj. 2023

 

10.48176/esmj.2023.102


View Detail >

Hum Genomics

Analysis of clinical and genomic profiles of therapy-related myeloid neoplasm in Korea

Yun J, Song H, Kim S-M, Kim S, Kwon SR, Lee YE, et al. Analysis of clinical and genomic profiles of therapy-related myeloid neoplasm in Korea. Hum Genomics. 2023;17(1).

 

10.1186/s40246-023-00458-8


View Detail >

Cancer Research and Treatment

Efficacy of Olaparib in Treatment-Refractory, Metastatic Breast Cancer with Uncommon Somatic BRCA Mutations Detected in Circulating Tumor DNA

Yoon J-K, Ahn J, Kim S, Kim H-P, Kang J-K, Bang D, et al. Efficacy of olaparib in treatment-refractory, metastatic breast cancer with uncommon somatic BRCA mutations detected in circulating tumor DNA. Cancer Res Treat. 2023;55(3):1048–52.

 

10.4143/crt.2022.1529


View Detail >